Article metrics

Download PDFPDF

2022-RA-1540-ESGO MITO 25.1: a randomized, molecular driven phase II trial of carboplatin-paclitaxel-bevacizumab vs carboplatin-paclitaxel-bevacizumab-rucaparib vs carboplatin-paclitaxel-rucaparib, selected according to HRD status, in patients with advanced (Stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer


Online download statistics by month:

Online download statistics by month: October 2022 to November 2023

Oct 20221102
Nov 20227106
Dec 20226907
Jan 20234506
Feb 20232008
Mar 20232204
Apr 20232003
May 20231703
Jun 20231402
Jul 2023905
Aug 20231204
Sep 20232203
Oct 20231404
Nov 20232206